1. |
Hellström A, Smith LE, Dammann O. Retinopathy of prematurity[J]. Lancet, 2013, 382(9902): 1445-1457. DOI: 10.1016/S0140-6736(13)60178-6.
|
2. |
中华医学会儿科学分会眼科学组. 早产儿视网膜病变治疗规范专家共识[J]. 中华眼底病杂志, 2022, 38(1): 10-13. DOI: 10.3760/cma.j.cn511434-20211119-00647.Ophthalmology Group of Pediatrics Society of Chinese Medical Association. Expert consensus on the treatment of retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2022, 38(1): 10-13. DOI: 10.3760/cma.j.cn511434-20211119-00647.
|
3. |
王慧冉, 罗荣. 早产儿视网膜病变发生及筛查现状[J]. 中国妇幼卫生杂志, 2022, 13(2): 1-5. DOI: 10.19757/j.cnki.issn1674-7763.2022.02.001.Wang HR, Luo R. Status of the occurrence and screening of retinopathy of prematurity[J]. Chinese Journal of Women and Children Health, 2022, 13(2): 1-5. DOI: 10.19757/j.cnki.issn1674-7763.2022.02.001.
|
4. |
Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition[J/OL]. Ophthalmology, 2021, 128(10): e51-e68[2021-07-08]. https://pubmed.ncbi.nlm.nih.gov/34247850/. DOI: 10.1016/j.ophtha.2021.05.031.
|
5. |
Zhang RH, Liu YM, Dong L, et al. Prevalence, years lived with disability, and time trends for 16 causes of blindness and vision impairment: findings highlight retinopathy of prematurity[J/OL]. Front Pediatr, 2022, 10: 735335[2022-03-11]. https://europepmc.org/article/MED/35359888. DOI: 10.3389/fped.2022.735335.
|
6. |
姜海涛, 李国仁. 我国早产儿视网膜病变的筛查现状[J]. 国际眼科杂志, 2021, 21(8): 1386-1389. DOI: 10.3980/j.issn.1672-5123.2021.8.15.Jiang HT, Li GR. Screening status of retinopathy of prematurity in China[J]. Int Eye Sci, 2021, 21(8): 1386-1389. DOI: 10.3980/j.issn.1672-5123.2021.8.15.
|
7. |
Wu Z, Zhao J, Lam W, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial[J]. Br J Ophthalmol, 2022, 106(7): 975-979. DOI: 10.1136/bjophthalmol-2020-318026.
|
8. |
Jin E, Yin H, Liu K, et al. Different types of hyperfluorescence observed in post anti-VEGF fluorescein angiographic patterns in retinopathy of prematurity patients[J/OL]. Front Med (Lausanne), 2022, 8: 800821[2022-01-24]. https://pubmed.ncbi.nlm.nih.gov/35141247/ DOI: 10.3389/fmed.2021.800821.
|
9. |
Bai Y, Nie H, Wei S, et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity[J]. Br J Ophthalmol, 2019, 103(4): 494-498. DOI: 10.1136/bjophthalmol-2017-311662.
|
10. |
Barry GP, Yu Y, Ying GS, et al. Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor[J]. Ophthalmology, 2021, 128(8): 1188-1196. DOI: 10.1016/j.ophtha.2020.12.028.
|
11. |
Kondo C, Iwahashi C, Utamura S, et al. Characteristics of eyes developing retinal detachment after anti-vascular endothelial growth factor therapy for retinopathy of prematurity[J/OL]. Front Pediatr, 2022, 10: 785292[2022-04-07]. https://pubmed.ncbi.nlm.nih.gov/35463897/. DOI: 10.3389/fped.2022.785292.
|
12. |
中华医学会眼科学分会眼底病学组. 中国早产儿视网膜病变筛查指南(2014年)[J]. 中华眼科杂志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.Ophthalmology Group of Fundus Society of Chinese Medical Association. Screening guidelines for retinopathy of prematurity in China (2014)[J]. Chin J Ophthalmol, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
|
13. |
李曼红, 王亮, 张自峰, 等. 两种抗VEGF药物治疗1型早产儿视网膜病变的疗效比较[J]. 国际眼科杂志, 2021, 21(5): 866-871. DOI: 10.3980/j.issn.1672-5123.2021.5.24.Li MH, Wang L, Zhang ZF, et al. Comparison of the effectiveness of conbercept versus ranibizumab in the treatment of type 1 retinopathy of prematurity[J]. Int Eye Sci, 2021, 21(5): 866-871. DOI: 10.3980/j.issn.1672-5123.2021.5.24.
|
14. |
林琳, 熊永强, 吕月娥, 等. 玻璃体腔注射康柏西普治疗早产儿视网膜病变疗效观察[J]. 中国斜视与小儿眼科杂志, 2022, 30(1): 32. DOI: 10.3969/J.ISSN.1005-328X.2022.01.011.Lin L, Xiong YQ, Lyu YE, et al. Observation of the curative effect of intravitreal injection of Conbercept in the treatment of retinopathy of prematurity[J]. Chinese Journal of Strabismus & Pediatric Ophthalmology, 2022, 30(1): 32. DOI: 10.3969/J.ISSN.1005-328X.2022.01.011.
|
15. |
王宗华, 李秋平, 杨秀梅, 等. 康柏西普和雷珠单抗治疗早产儿视网膜病变的疗效分析[J]. 中华眼视光学与视觉科学杂志, 2021, 23(11): 858-863. DOI: 10.3760/cma.j.cn115909-20210208-00054.Wang ZH, Li QP, Yang XM, et al. Comparison of the treatment outcomes for retinopathy of prematurity with an intravitreal injection of Conbercept or Ranibizumab[J]. Chin J Optom Ophthalmol Vis Sci, 2021, 23(11): 858-863. DOI: 10.3760/cma.j.cn115909-20210208-00054.
|
16. |
Yi Z, Su Y, Zhou Y, et al. Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants[J]. Curr Eye Res, 2016, 41(8): 1092-1097. DOI: 10.3109/02713683.2015.1084643.
|
17. |
熊薇薇, 杨晖, 傅征, 等. 激光光凝及抗VEGF治疗早产儿视网膜病变阈值前病变1型的疗效对比[J]. 眼科学报, 2021, 36(10): 776-780. DOI: 10.3978/j.issn.1000-4432.2021.09.05.Xiong WW, Yang H, Fu Z, et al. Comparison of the efficacy of laser photocoagulation and anti-VEGF in the treatment of type 1 prethreshold retinopathy of prematurity[J]. Eye Science, 2021, 36(10): 776-780. DOI: 10.3978/j.issn.1000-4432.2021.09.05.
|
18. |
Yang XM, Zhao YX, Wang ZH, et al. Effect of anti-VEGF treatment on retinopathy of prematurity in zone Ⅱ stage 3[J]. Int J Ophthalmol, 2018, 11(4): 641-644. DOI: 10.18240/ijo.2018.04.17.
|
19. |
Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial[J]. Lancet, 2019, 394(10208): 1551-1559. DOI: 10.1016/S0140-6736(19)31344-3.
|
20. |
Jin E, Yin H, Li X, et al. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity[J]. Retina, 2018, 38(8): 1595-1604. DOI: 10.1097/IAE.0000000000001763.
|